Atomwise's AtomNet platform has computationally screened over three trillion synthesizable chemical compounds across more than 600 disease targets to identify therapeutic candidates. In landmark research, AtomNet was applied to 318 targets through collaborations with over 250 academic labs across 30 countries, successfully identifying novel hits for 235 targets and demonstrating superior hit success rates over traditional high-throughput screening. Programs developed from the platform target immune and inflammatory diseases.
Cyborg Score Rationale
Atomwise demonstrates strong technical differentiation through proven AI capabilities validated across 318 targets, growing internal pipeline transition, and experienced leadership with regulatory focus. Recent traction includes CMO appointment and development candidate nomination. Primary risks include clinical development execution, competitive AI drug discovery landscape, and path to revenue from internal programs.
Top Insights
The company is advancing a TYK2 inhibitor to clinical trials targeting inflammatory bowel disease, systemic lupus, psoriasis, and related immune-mediated conditions.
Atomwise nominated its first AI-driven development candidate focused on TYK2 inhibition, marking a significant milestone in its transition to pharmaceutical development.
Atomwise signed a multi-target AI drug discovery collaboration with Sanofi valued at approximately $20 million upfront with up to $1.2 billion in potential milestones and royalties.
The AIMS project demonstrated significant potential through analysis of 318 targets in collaboration with more than 250 academic labs across 30 countries, establishing AI as a viable alternative to traditional screening methods.
Named Competitors
Exscientia — AI-driven drug discovery platform for small-molecule design
Schrodinger — Computational chemistry and AI platform for drug discovery
Recursion — AI platform combining biology and chemistry for drug discovery
Recent Developments
(2025) Appointed Dr. Neely Mozaffarian as Chief Medical Officer to advance TYK2 inhibitor and internal pipeline into clinical trials
(2024) Published landmark 318-target study in Nature Scientific Reports demonstrating AtomNet's ability to discover structurally novel compounds across diverse therapeutic targets
(2024) Nominated first AI-driven development candidate, an orally bioavailable TYK2 inhibitor for immune and inflammatory diseases
Open the full interactive Atomwise Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.